trial
as of 2026-07-01A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
NCTId NCT03669640
at a glance
Phase 2 · Terminated
Enrollment 131 (actual)
Sponsored by Hoffmann-La Roche
Primary completion 2023-03-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Terminated
Enrollment
131 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2018-12-04
Primary completion
2023-03-12
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Sponsors
Hoffmann-La RocheLead Sponsor
Sites
45 total
Bellflower, United StatesGarden Grove, United StatesGlendale, United StatesLemon Grove, United StatesMontclair, United StatesRiverside, United StatesSan Diego, United StatesStanford, United StatesTorrance, United StatesNew Haven, United StatesLauderhill, United StatesLeesburg, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
131
Phase
PHASE2
Primary Completion Date
2023-03-12
Status
TERMINATED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication
indication